Lannett Co., Inc.

NYSE:LCI   11:59:38 AM EDT
1.46
+0.10 (+7.35%)
Products, Regulatory

Lannett Co Announces Submission Of Investigational New Drug (IND) Application For Biosimilar Insulin Glargine

Published: 12/20/2021 12:03 GMT
Lannett Co., Inc. (LCI) - Lannett Announces Submission of Investigational New Drug (ind) Application for Biosimilar Insulin Glargine.
Lannett Company Inc - Anticipates Commencing Pivotal Clinical Trial in March 2022.
Lannett Company Inc - Anticipate Filing Biologics License Application (bla) in Early 2023 and Potentially Launching Product by Early 2024.